Incyte and TG Therapeutics are seeing strong share growth, backed up by booming revenue and earnings.

fool.com - 2026-07-08 20:05:00

TGTX initiates a phase II study evaluating Briumvi in adult patients with treatment-resistant schizophrenia. Shares rise.

zacks.com - 2026-07-07 10:01:28

Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients Phase 2 trial to evaluate the effects of B-cell depletion with BRIUMVI in approximately 60 patients with treatment-resistant schizophrenia based on emerging evidence linking immune dysfunction to disease in a subset of patients

globenewswire.com - 2026-07-06 07:30:00

TG Therapeutics continues to witness rising Briumvi demand. Investors are closely watching the sales numbers of the drug.

zacks.com - 2026-07-03 09:55:45

TG Therapeutics Inc. (NASDAQ:TGTX) shares are trading higher on Thursday as traders keep leaning into recent upbeat clinical updates around BRIUMVI.

benzinga.com - 2026-06-18 15:29:40

TG Therapeutics stock is on an absolute rampage, climbing 70% in roughly the first six months of the year, as the biotech takes on Roche.

investors.com - 2026-06-17 08:00:03

TG Therapeutics (TGTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

zacks.com - 2026-06-11 06:16:07

TG Therapeutics gains after positive phase I data for subcutaneous Briumvi in myasthenia gravis or MG, while a phase II study in MG gets underway.

zacks.com - 2026-06-10 10:21:05

TG Therapeutics, Inc. (TGTX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

seekingalpha.com - 2026-06-09 17:12:13

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11) Potential registration-directed Phase 2 trial utilizes novel sequential treatment approach designed to combine rapid symptom control of FcRn inhibition with sustained disease modification of B-cell depletion therapy NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc.

globenewswire.com - 2026-06-09 07:30:00

82% of subjects achieved an MCID in their MG-ADL with a mean >4 point improvement in MG-ADL observed in Phase 1 study of Subcutaneous BRIUMVI in patients with MG (n=11)

globenewswire.com - 2026-06-09 07:30:00

TG Therapeutics (TGTX) reported earnings 30 days ago. What's next for the stock?

zacks.com - 2026-06-05 12:35:33

TG Therapeutics jumps 9.5% after phase I data show that subcutaneous Briumvi achieved over 60% bioavailability, sustained drug exposure, and was well tolerated.

zacks.com - 2026-06-04 12:01:16

TG Therapeutics, Inc.'s Phase 1 results of subcutaneous Briumvi are a major de-risking event for TG's most important clinical development program. SC Briumvi's bioavailability, safety, and tolerability support expectations of non-inferiority to IV Briumvi, with phase 3 topline data expected late 2026 or early 2027. IV Briumvi's sequential growth has improved, with 2026 U.S. sales guidance raised to $885–900 million and with potential for beat-and-raise trends to continue.

seekingalpha.com - 2026-06-04 09:00:00

Shares of TG Therapeutics Inc (NASDAQ:TGTX) are climbing Wednesday afternoon following the release of early-stage clinical trial data for a new formulation of its multiple sclerosis drug, BRIUMVI. Here's what investors need to know.

benzinga.com - 2026-06-03 15:19:00

Pharmacokinetic and pharmacodynamic data support quarterly subcutaneous BRIUMVI dosing regimen currently under evaluation in fully enrolled Phase 3 trial; Top-line Phase 3 data expected year-end 2026 or early 2027

globenewswire.com - 2026-06-03 07:30:00

NEW YORK, June 02, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Goldman Sachs 47th Annual Healthcare Conference, being held at the Loews Miami Beach Hotel, in Miami Beach, Florida on June 8-10, 2026.

globenewswire.com - 2026-06-02 07:30:00

Treatment with BRIUMVI reduced annualized relapse rate by 56.7% vs. teriflunomide in treatment-naïve patients BRIUMVI demonstrated significant improvements across disability, MRI outcomes, and no evidence of disease activity (NEDA-3) in treatment naïve patients supporting early use of high-efficacy therapy NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the publication of data from a post-hoc pooled analysis of the Phase 3 ULTIMATE I and II studies evaluating BRIUMVI® (ublituximab-xiiy) in treatment-naïve adult patients with relapsing forms of multiple sclerosis (RMS).

globenewswire.com - 2026-06-01 07:30:00

TG Therapeutics remains a "Strong Buy" as BRIUMVI drives robust revenue growth and pipeline expansions. The company raised 2026 BRIUMVI sales guidance to $885–$900 million, reflecting 63% year-over-year Q1 sales growth and strong market momentum. Phase 3 ENHANCE trial success with single 600 mg IV BRIUMVI dosing supports label expansion and competitive positioning in the RMS market.

seekingalpha.com - 2026-05-28 13:35:11

TG Therapeutics announces that Briumvi's late-stage ENHANCE study met its goal, supporting a potential single-infusion regimen for relapsing MS patients.

zacks.com - 2026-05-28 11:35:19

Expense ratios, yield, and sector breadth set these healthcare ETFs apart-see how their risk profiles and portfolio strategies compare.

fool.com - 2026-05-28 08:07:09

NEW YORK, May 28, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 2-4, 2026.

globenewswire.com - 2026-05-28 07:30:00

Phase 3 trial met its primary endpoint, demonstrating bioequivalent drug exposure between the currently approved BRIUMVI Day 1 and Day 15 initiation dosing and a new single infusion on Day 1 only

globenewswire.com - 2026-05-27 07:30:00

NEW YORK, May 26, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the upcoming schedule of presentations highlighting BRIUMVI® (ublituximab-xiiy) data in adults with relapsing forms of multiple sclerosis (RMS) at the 2026 Consortium of Multiple Sclerosis Centers (CMSC) annual meeting, being held May 27-29, 2026 in Charlotte, N.C. Abstracts are available on the CMSC website at http://www.mscare.org/2026 and data presentations are also available and can be accessed either on the 2026 CMSC meeting app or on TG's website at www.tgtherapeutics.com/publications. All TG data will be presented by the respective authors during the CMSC conference on Thursday, May 28th, 2026. Additional details of the presentation schedule can be found below.

globenewswire.com - 2026-05-26 07:30:00

TG Therapeutics gains on strong Briumvi sales growth, higher 2026 revenue guidance and advancing late-stage studies in RMS.

zacks.com - 2026-05-20 11:56:28

TG Therapeutics Inc (NASDAQ:TGTX) is trading down 1.2% at $42.35, after last week being rejected by the overhead $44 ceiling.

schaeffersresearch.com - 2026-05-11 14:00:25

TG Therapeutics misses Q1 earnings estimates, but strong Briumvi sales drive y/y revenues. Shares rise as the company raises 2026 revenue outlook.

zacks.com - 2026-05-07 13:11:18

TG Therapeutics, Inc. (TGTX) Q1 2026 Earnings Call Transcript

seekingalpha.com - 2026-05-06 13:11:20

TG Therapeutics (TGTX) came out with quarterly earnings of $0.17 per share, missing the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.03 per share a year ago.

zacks.com - 2026-05-06 09:25:17

First quarter 2026 total global revenue of approximately $205 million, including BRIUMVI U.S. net revenue of approximately $195 million Raises full year 2026 total global revenue target to approximately $925 million and raises full year 2026 BRIUMVI U.S. net product revenue target to $885-900 million Conference call to be held today, Wednesday, May 6, 2026, at 8:30 AM ET NEW YORK, May 06, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) (the Company or TG Therapeutics) today announced its financial results for the first quarter of 2026, along with recent company developments and provided an update on 2026 financial guidance. Michael S.

globenewswire.com - 2026-05-06 07:00:00

NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced that a conference call will be held, Wednesday, May 6, 2026, at 8:30 AM ET to discuss results for the first quarter 2026 and to provide a business outlook for the remainder of 2026. Michael S.

globenewswire.com - 2026-04-30 07:30:00

Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-28 11:08:34

TG Therapeutics (TGTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

zacks.com - 2026-04-27 11:05:27

TG Therapeutics is downgraded from Strong Buy to Buy after a 17% rally, reflecting a now fairer valuation. Briumvi IV continues to gain market share in MS, while the SC version's trial is fully enrolled and could double the addressable market. Management guides conservatively for 2026 Briumvi U.S. net revenue of $825–$850 million and maintains disciplined operating expense targets.

seekingalpha.com - 2026-04-18 22:32:28

TG Therapeutics completes enrollment in a phase III study of subcutaneous Briumvi for treating RMS in adults, with data expected by late 2026 or early 2027.

zacks.com - 2026-04-16 10:41:53